Press Release Archives - Metrion Biosciences

Metrion Biosciences and LifeArc sign collaboration agreement

Andy Southan 2019-01-29T12:03:20+00:00

Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery Novel small molecule programme aims to address major unmet medical need in neuroscience Collaboration focused on specific potassium ion channel target Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and [...]

Metrion Biosciences and LifeArc sign collaboration agreement Andy Southan 2019-01-29T12:03:20+00:00

Metrion Biosciences strengthens its drug discovery leadership team

Sophie Rose 2018-09-17T09:49:30+00:00

Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has made two senior appointments [...]

Metrion Biosciences strengthens its drug discovery leadership team Sophie Rose 2018-09-17T09:49:30+00:00

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services

Andy Southan 2018-09-10T14:38:27+00:00

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services Agreement enables customers to access a broader range of drug discovery expertise. Metrion Biosciences Limited (“Metrion”), the specialist ion channel CRO and drug discovery company, and AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve [...]

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services Andy Southan 2018-09-10T14:38:27+00:00

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award

Sophie Rose 2018-09-10T14:40:22+00:00

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery • Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis • Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors Cambridge, UK, 28 August 2018: Metrion [...]

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award Sophie Rose 2018-09-10T14:40:22+00:00

Metrion appoints two new Board Directors

Andy Southan 2018-08-01T14:30:28+00:00

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Metrion appoints two new Board Directors Andy Southan 2018-08-01T14:30:28+00:00

Metrion Biosciences establishes Scientific Advisory Board

Andy Southan 2018-11-26T15:28:23+00:00

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences establishes Scientific Advisory Board Andy Southan 2018-11-26T15:28:23+00:00

Innovate UK Biomedical Catalyst Feasibility Award

Metrion 2018-07-18T16:02:11+00:00

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Innovate UK Biomedical Catalyst Feasibility Award Metrion 2018-07-18T16:02:11+00:00

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.

Andy Southan 2018-04-13T13:35:54+00:00

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Novel potassium channel inhibitors acquired from Japan Tobacco Inc. Andy Southan 2018-04-13T13:35:54+00:00

Metrion Biosciences opens SyndicateRoom investment round

Andy Southan 2018-03-09T15:53:46+00:00

Cambridge, UK, 16 January 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and online investment platform SyndicateRoom, announced today the opening of a £600k investment round in Metrion. Metrion will use the funds to expand its rapidly growing fee-for-service business. This is the first private investment round for [...]

Metrion Biosciences opens SyndicateRoom investment round Andy Southan 2018-03-09T15:53:46+00:00